Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma

Andrew Kowalski, David G. Coffey, Benjamin Diamond, James E. Hoffman, Marcella Kaddoura, Jill Lykon, Francesco Maura, Yahirini Rodriguez-Martinez, Suzan Rosen, Faika Shah, Dennis Verducci, Ola Landgren, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 2389.

https://doi.org/10.1182/blood-2024-203763

Published: 2024

Journal Articles

Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias

Yong Zhang, David G. Coffey, Elizabeth Hill, Frank Cross, Jr., Reena Philip, Marc R. Theoret, Ola Landgren, Andrea C Baines, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 1907.

https://doi.org/10.1182/blood-2024-202574

Published: 2024

Journal Articles

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Binod Dhakal, Hang Quach, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Peter Tan, Tara Cochrane, Hanlon Sia, Jeffrey A. Zonder, Camille Martinet, Dominique Duchesne, Andrew Garton, Vinu Menon, Beata Holkova, Cyril Konto, Lida Pacaud, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2024-209952

Published: 2024

Journal Articles

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7059.

https://doi.org/10.1182/blood-2024-201563

Published: 2024

Journal Articles

Advance Multicenter Clinical Trial: MRD-Driven Therapy in Newly Diagnosed Multiple Myeloma Patients

Ola Landgren, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 7035.

https://doi.org/10.1182/blood-2024-202079

Published: 2024

Journal Articles

Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab

Andrew Kowalski, Jill Lykon, Benjamin Diamond, David G. Coffey, Marcella Kaddoura, Francesco Maura, James E. Hoffman, Dickran Kazandjian, Ola Landgren

Blood (2024) 144 (Supplement 1): 932.

https://doi.org/10.1182/blood-2024-203426

Published: 2024

Journal Articles

Long Term Risk of Lymphoid Malignancies Among U.S. Service Members Exposed to Burn Pits in Iraq Vs. Never Deployed

Ian Robertson, Robert Sgrignoli, Alexander Dew, Sarah Darmon, Ola Landgren, Dickran Kazandjian, Christin DeStefano

Blood (2024) 144 (Supplement 1): 7821.

https://doi.org/10.1182/blood-2024-198899

Published: 2024

Journal Articles

Enhanced Detection of M-Protein in Non-Secretory and Oligo-Secretory Multiple Myeloma Using MALDI-TOF Mass Spectrometry

Gil Hevroni, Katie Thoren, Dan C. Qu, Elizabeth Lyubchenko, Elena Bosack, James E. Hoffman, Ola Landgren, Benjamin Diamond, Dickran Kazandjian, David G. Coffey

Blood (2024) 144 (Supplement 1): 6847.

https://doi.org/10.1182/blood-2024-205107

Published: 2024

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2024) 144 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2024-193966

Published: 2024

Journal Articles

ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

Blood (2024) 144 (Supplement 1): 496.

https://doi.org/10.1182/blood-2024-205083

Published: 2024

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Blood (2024) 144 (Supplement 1): 2870.

https://doi.org/10.1182/blood-2024-210872

Published: 2024

Journal Articles

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure

Dickran Kazandjian, Christin DeStefano, Alexander Dew, Elizabeth Hill, Katie Thoren, Ola Landgren

Blood (2024) 144 (Supplement 1): 4669.

https://doi.org/10.1182/blood-2024-202196

Published: 2024

Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Blood (2024) 144 (4): 359–367.

https://doi.org/10.1182/blood.2024024371

Published: 2024

Includes: Supplemental data

Journal Articles

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 4707.

https://doi.org/10.1182/blood-2023-186241

Published: 2023

Journal Articles

Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience

Andrew Kowalski, Jillian Lorayne Lykon, Benjamin Diamond, David Coffey, Marcella Kaddoura, Francesco Maura, James E. Hoffman, Dickran Kazandjian, Ola Landgren

Blood (2023) 142 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2023-187086

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

Long Term Cancer Risk of U.S. Service Members Exposed to Burn Pits during Military Deployment to Iraq from 2006-2008: A Retrospective Cohort Study

Robert Sgrignoli, Matthew Joseph Rendo, Alexander Dew, Ian Robertson, Sarah Darmon, Ola Landgren, Dickran Kazandjian, Christin DeStefano

Blood (2023) 142 (Supplement 1): 6621.

https://doi.org/10.1182/blood-2023-173557

Published: 2023

Journal Articles

CYT-338 NK Cell Engager Mutispecific Antibody Engagement of NKp46 Activation Receptor Overcomes Anti-CD38 Mab Mediated Fratricide of NK Cells and Accords Enhanced Cancer Immunotherapy

Vishal Khairnar, Liang Lin, Hao-Ming Chang, Sourindra Maiti, Solgalim Diaz, Ofer Mandelboim, Tariq Mughal, Dan Chiche, Elisabetta Burchi, Armand Bensussan, Jean Kadouche, Ola Landgren, Dickran Kazandjian, Armin Rath, Daniel Teper, Wei Li, Antonio Arulanandam

Blood (2023) 142 (Supplement 1): 6725.

https://doi.org/10.1182/blood-2023-190613

Published: 2023

Journal Articles

Advance Multicenter Clinical Trial: MRD-Driven Therapy in Newly Diagnosed Multiple Myeloma Patients

Ola Landgren, Francesco Maura, Dickran Kazandjian

Blood (2023) 142 (Supplement 1): 3392.

https://doi.org/10.1182/blood-2023-186834

Published: 2023

Journal Articles

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Hang Quach, Doug Sborov, Dickran Kazandjian, Andrew Spencer, Michael Low, Susan Bal, Natalie S. Callander, Huan Cheng, Sheel Patel, Rocco J. Crescenzo, Amit Agarwal, Binod Dhakal

Blood (2023) 142 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2023-178735

Published: 2023

NARROW

Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma

Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Advance Multicenter Clinical Trial: MRD-Driven Therapy in Newly Diagnosed Multiple Myeloma Patients

Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab

Long Term Risk of Lymphoid Malignancies Among U.S. Service Members Exposed to Burn Pits in Iraq Vs. Never Deployed

Enhanced Detection of M-Protein in Non-Secretory and Oligo-Secretory Multiple Myeloma Using MALDI-TOF Mass Spectrometry

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Long Term Cancer Risk of U.S. Service Members Exposed to Burn Pits during Military Deployment to Iraq from 2006-2008: A Retrospective Cohort Study

CYT-338 NK Cell Engager Mutispecific Antibody Engagement of NKp46 Activation Receptor Overcomes Anti-CD38 Mab Mediated Fratricide of NK Cells and Accords Enhanced Cancer Immunotherapy

Advance Multicenter Clinical Trial: MRD-Driven Therapy in Newly Diagnosed Multiple Myeloma Patients

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only